Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Brizo
Therapeutic Area : Urology
Study Phase : Undisclosed
Sponsor : Clalit
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 07, 2022
Lead Product(s) : Brizo
Therapeutic Area : Urology
Highest Development Status : Undisclosed
Sponsor : Clalit
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Recipient : Dr. Lila Nachtigall Rapid Medical Research, New York
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 30, 2011
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Recipient : Dr. Lila Nachtigall Rapid Medical Research, New York
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Clalit
Deal Size : Inapplicable
Deal Type : Inapplicable
A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 05, 2010
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Clalit
Deal Size : Inapplicable
Deal Type : Inapplicable